MaaT Pharma presents positive results for MaaT013, its most advanced drug candidate, at ASH 2023 and details the ongoing Phase 2b trial evaluating MaaT033
• Positive efficacy results from 111 acute graft-versus-host disease (aGvHD) patients treated with MaaT013 under the compassionate access program and good product safety were presented at the conference of ASH 2023.
• An overall gastrointestinal response rate (GI-ORR) of 53%, observed on day 28, had a positive and significant impact on overall survival (OS) in responding patients.
• The overall survival (OS) results were even more pronounced (81% for responders and 8% for non-responders) for the population of patients with a profile similar to those treated in the ARES clinical trial (GI-ORR of 61% on the 28th day).
• The design of the ongoing Phase 2b trial in Europe evaluating MaaT033 in patients receiving allogeneic hematopoietic stem cell transplantation was presented at the ASH 2023 conference.
To receive all financial information from MaaT Pharma in real time and for any questions, you can contact us via the following address: [email protected]